摘要
目的探讨Cronkhite-Canada综合征(CCS)的临床特点和治疗方法。方法分析1999年10月至2018年1月北京协和医院确诊的CCS患者的临床特点,并以2012年为界分为两组进行诊治情况的对比。结果共26例患者,男18例,女8例;起病年龄(58.7±7.0)岁;首发症状主要是腹泻(12/26)和味觉减退(9/26),病理以增生性息肉(16/26)最多见;均采用糖皮质激素治疗,2013年之后的患者泼尼松起始用量略增加[(0.8±0.4)mg/(kg·d)对(0.7±0.2)mg/(kg·d),P=0.38],且有2例加用了免疫抑制剂治疗后才达到临床症状及内镜表现好转。治疗的临床症状好转率达92%(23/25),内镜表现好转率达88.9%(16/18),有2例分别在起病5年和1年后出现癌变。结论 CCS的诊断率近年呈上升趋势,免疫抑制剂治疗对于激素疗效不佳的患者亦可取得一定的疗效。
Objective To explore clininal characteristics the diagnosis and treatment of Cronkhite-Canada syndrome(CCS).Methods Clinical characteristics were retrospectively analyzed in all CCS patients diagnosed from October 1999 to January 2018 in Peking Union Medical College Hospital.The diagnostic and therapeutic strategies were compared between patients who were diagnosed before 2012 and patients after 2013.Results There were 26 patients enrolled in this study,in which 18 patients were male.The CCS onset age was(58.7±7.0) years old.Initial symptoms were mainly diarrhea(12/26) and hypogeusia(9/26).The pathology was mainly hyperplastic polyp(16/26).All patients were treated with glucocorticoid therapy.The starting dose of steroid was slightly increased after 2013 [(0.8±0.4)mg/(kg·d) vs(0.7±0.2) mg/(kg·d),P=0.38].Two patients were prescribed with immunosuppressors because of poor effects of steroid,and they got both clinical and endoscopic resolution.Clinical outcomes were improved in 23/25(92%),and polyps were decreased in 16/18 patients.Two patients were detected with colon carcinoma in the second and fifth year respectively.Conclusion The diagnosis rate seems to increase in these years.In treating CCS,immunosuppressors might get better effects on those steroid-resistant patients.
作者
罗涵青
李媛
周炜洵
吴东
钱家鸣
LUO Han-qing;LI Yuan;ZHOU Wei-xun;WU Dong;QIAN Jia-ming(Department of Gastroenterology, Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2018年第12期1177-1180,共4页
Chinese Journal of Practical Internal Medicine
基金
公益性行业科研专项(201502005)